Welcome to our dedicated page for Cooper news (Ticker: COO), a resource for investors and traders seeking the latest updates and insights on Cooper stock.
CooperCompanies (Nasdaq: COO) is a global medical device company with two main business units, CooperVision and CooperSurgical, and its news flow reflects this mix of vision care and women’s health activities. Company press releases regularly provide updates on quarterly and annual financial results, including revenue, earnings per share, margins, and free cash flow, along with commentary from management on operational performance and priorities.
Investors following COO news will see detailed segment information for CooperVision and CooperSurgical, such as revenue by product category and geography, as well as explanations of non‑GAAP metrics, constant currency growth, and organic growth. Releases also describe reorganization and integration efforts, business optimization charges, and product line exits, offering context on how these actions affect reported margins and future cost structure.
CooperCompanies’ news also covers corporate governance and strategic topics. Recent announcements include changes in Board leadership, the appointment of new independent directors, and a formal strategic review of the company’s businesses, corporate structure, and capital allocation priorities. The company has disclosed cooperation agreements with investment partners and expansions of its share repurchase program, including a Board‑approved increase that brought total authorization to $2 billion.
In addition, CooperCompanies issues notices about upcoming earnings releases, conference calls, and participation in healthcare investment conferences, where senior executives present and answer questions. For those interested in the broader eye care landscape, external communications related to CooperVision highlight its role in contact lenses and myopia management. This news page brings together these financial, strategic, and industry‑related updates in one place for users tracking COO.
CooperVision (Nasdaq: COO) launched MiSight 1 day in Japan on Feb 10, 2026, marking the first soft contact lens authorized by Japan's Ministry of Health, Labor and Welfare for children to correct myopia and slow progression.
The lens is approved in >40 countries, features ActivControl technology, and showed an average 59% reduction in myopia progression after three years. Japan represents ~12% of the global contact lens market and faces an estimated 77% myopia rate among elementary school children.
CooperCompanies (Nasdaq: COO) will report first quarter 2026 financial results on Thursday, March 5, 2026 at 4:15 PM ET. A conference call will follow at 5:00 PM ET with dial-in 800-715-9871 (conference ID 6529381). A live audio webcast and replay are available at the company investor website.
CooperCompanies (Nasdaq: COO) will present at the J.P. Morgan Healthcare Conference on January 14, 2026. Al White, President and CEO, is scheduled to speak in a session beginning at 5:15pm ET. A live and archived webcast will be available on CooperCompanies' investor website for those who cannot attend the session in person.
CooperCompanies (Nasdaq: COO) appointed Walter M Rosebrough, Jr. as an independent director effective Jan 3, 2026 and entered a Cooperation Agreement with Browning West on Dec 23, 2025.
The Board agreed to seriously consider Mr. Rosebrough for Board Chair by end of 2026, to appoint a new independent director with medical technology experience (with Browning West’s mutual agreement), and to accept Browning West’s customary standstill and voting commitments. The Cooperation Agreement will be filed as an exhibit to a Form 8-K with the SEC.
CooperCompanies (Nasdaq: COO) announced that its Board appointed Colleen Jay as Chair, effective January 2, 2026, succeeding Robert Weiss, who will remain on the Board and stand for reelection for one final term.
The Board launched a formal strategic review of the company’s businesses, corporate structure, strategy, operations and capital allocation to identify opportunities to simplify the business and unlock long-term shareholder value, including partnerships, joint ventures, divestitures, mergers and other transactions. The company said it expects to focus capital deployment on repurchasing shares under its recently announced $2 billion share repurchase program.
CooperCompanies (Nasdaq: COO) reported fiscal Q4 2025 revenue of $1,065.2M (+5% reported, +3% organic) and fiscal 2025 revenue of $4,092.4M (+5% reported, +4% organic). Q4 GAAP diluted EPS was $0.43 (down 27%); fiscal 2025 GAAP EPS was $1.87 (down 4%). Q4 non-GAAP diluted EPS was $1.15 (+11%); fiscal 2025 non-GAAP EPS was $4.13 (+12%).
Q4 free cash flow was $149.8M; fiscal 2025 free cash flow was $433.7M. The company repurchased $197.3M of stock in Q4 and expanded its buyback authorization by $1B to $2B (about $1B remaining). Reorganization and integration activity generated ~$89M of charges with expected annual pre-tax savings of ~$50M beginning fiscal 2026.
Fiscal 2026 guidance: total revenue $4,299–$4,338M, non-GAAP EPS $4.45–$4.60, and free cash flow $575–$625M; long-term free cash flow objective of more than $2.2B for 2026–2028.
CooperCompanies (Nasdaq: COO) announced it will report fourth quarter and full year 2025 financial results on Thursday, December 4, 2025 with a results release at 4:15 PM ET.
The company will host a conference call at 5:00 PM ET the same day to discuss results and corporate developments. Dial-in: 800-715-9871; conference ID: 2700541. A simultaneous audio webcast and subsequent replay will be available at http://investor.coopercos.com.
The Canadian Association of Optometrists (CAO) has launched a new digital awareness campaign during Children's Vision Month in October, focusing on children's vision care and the growing myopia epidemic. The campaign, supported by various optometry associations and industry sponsors including CooperVision (NYSE:COO) and Alcon, emphasizes that eye issues aren't always obvious.
The initiative promotes comprehensive eye exams starting at 6-9 months of age, with follow-ups between ages 2-5, and annually until age 19. The campaign highlights concerning statistics, including projections that myopia will affect 50% of the world's population by 2050. The campaign will run across multiple social media platforms in both English and French.
CooperCompanies (Nasdaq: COO) has announced a significant expansion of its share repurchase program, with the Board of Directors approving a $1 billion increase, bringing the total program to $2 billion.
CEO Al White emphasized that this decision reflects the company's strong balance sheet, robust cash flow generation, and the Board's confidence in Cooper's long-term growth prospects. The program will be executed through open market or private purchases, with timing and amount dependent on market conditions. The program has no expiration date but can be suspended or discontinued at any time.
CooperCompanies (Nasdaq: COO) reported Q3 2025 financial results with revenue increasing 6% year-over-year to $1.06 billion. CooperVision revenue grew 6% to $718.4 million, while CooperSurgical revenue rose 4% to $341.9 million.
The company's GAAP diluted EPS decreased 6% to $0.49, while non-GAAP diluted EPS increased 15% to $1.10. Despite revenues below expectations, Cooper raised its earnings guidance, projecting improved revenue in Q4 and fiscal 2026. The company generated strong margins and robust free cash flow of $164.6 million.
During Q3, Cooper repurchased $52.1 million of common stock at an average price of $71.97. The company updated its fiscal 2025 guidance, expecting total revenue of $4,076-$4,096 million with organic growth of 4-4.5%, and non-GAAP diluted EPS of $4.08-$4.12.